Search results for "obesity drug"

“Half the Price of Mounjaro”: South Korea’s First Homegrown Obesity Drug Epe Enters the Market

“Half the Price of Mounjaro”: South Korea’s First Homegrown Obesity Drug Epe Enters the Market

The first domestically developed obesity medication is entering South Korea’s weight-loss market, long dominated by foreign pharmaceuticals such as...
Lexraza Developer and Lilly Obesity Chief to Headline Global Clinical Trial Summit in Seoul

Lexraza Developer and Lilly Obesity Chief to Headline Global Clinical Trial Summit in Seoul

What will it take to build on the success of Lexraza, South Korea’s landmark lung cancer drug, and propel it into the next generation of...
Hanmi’s ‘Epe’ Wins MFDS Approval, Becoming South Korea’s First Homegrown GLP-1 Obesity Drug

Hanmi’s ‘Epe’ Wins MFDS Approval, Becoming South Korea’s First Homegrown GLP-1 Obesity Drug

A domestically developed therapy has entered South Korea’s obesity treatment market, long dominated by imported...
To Curb GLP-1 Misuse, Experts Urge Tracking Who Gets Prescribed Wegovy and Mounjaro—and Why

To Curb GLP-1 Misuse, Experts Urge Tracking Who Gets Prescribed Wegovy and Mounjaro—and Why

As the adoption of GLP-1 receptor agonist obesity medications such as Wegovy and Mounjaro accelerates, medical experts...
Kyungdong Pharmaceutical and AUL Bio Seek Phase 1 Approval for Once-Monthly Obesity Drug AUL009

Kyungdong Pharmaceutical and AUL Bio Seek Phase 1 Approval for Once-Monthly Obesity Drug AUL009

Kyungdong Pharmaceutical announced Sept. 2 that it has submitted an investigational new drug application to the...
Hanmi Pharmaceutical Nears Korean Launch for Obesity Drug EPPE After Five-Year Detour

Hanmi Pharmaceutical Nears Korean Launch for Obesity Drug EPPE After Five-Year Detour

Licensed out to French pharmaceutical giant Sanofi in 2015 and returned five years later, Hanmi Pharmaceutical’s...
Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports

Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports

GLP-1 (glucagon-like peptide-1) class medications, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, are...
Hanmi Licenses Muscle-Preserving Obesity Drug Candidate to Genentech in $2.3 Billion Deal

Hanmi Licenses Muscle-Preserving Obesity Drug Candidate to Genentech in $2.3 Billion Deal

Hanmi Pharmaceutical has entered into an exclusive global licensing agreement with Genentech, a member of the Roche...
JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide

JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide

JW Pharmaceutical announced on Aug. 18 that it has submitted an Investigational New Drug application to South Korea’s...
Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival

Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival

Olix announced on July 30 that its obesity drug candidate, "OLX501A," significantly outperformed a global rival...